Baseline BML score and changes in BML score at 36 months for patients with BML at baseline in the medial subregions
| SrRan 1 g/day | SrRan 2 g/day | Placebo | p Value* | Placebo versus SrRan 1 g/day p Value** | Placebo versus SrRan 2 g/day p Value** | SrRan 1 g versus SrRan 2 g/day p Value** | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean±SD or % | n | Mean±SD or % | n | Mean±SD or % | n | |||||
| Medial compartment | ||||||||||
| Presence of BML at baseline: %, n | 27% | 31 | 22% | 23 | 27% | 30 | 0.596† | |||
| Baseline BML score | 1.52±0.68 | – | 1.22±0.52 | – | 1.77±0.97 | – | 0.054 | >0.9999 | 0.061 | 0.190 |
| 36 months | ||||||||||
| Difference from baseline | −0.39±0.76 | – | −0.50±0.56 | – | 0.19±0.81 | – | 0.0002 | 0.002 | 0.001 | >0.9999 |
| Increase | 13% | 3 | 5% | 1 | 38% | 8 | ||||
| Decrease | 52% | 12 | 55% | 11 | 29% | 6 | ||||
| Stable | 35% | 8 | 40% | 8 | 33% | 7 | ||||
| Total | 23 | 20 | 21 | 0.069† | 0.357 | 0.092 | >0.9999 | |||
| Medial femur | ||||||||||
| Presence of BML at baseline: %, n | 21% | 24 | 17% | 18 | 21% | 24 | 0.675† | |||
| Baseline BML score | 1.25±0.61 | – | 1.00±0.00 | – | 1.54±0.83 | – | 0.011 | 0.385 | 0.013 | 0.229 |
| 36 months | ||||||||||
| Difference from baseline | −0.47±0.60 | 24 | −0.56±0.48 | 18 | 0.11±0.83 | 24 | 0.002 | 0.014 | 0.006 | >0.9999 |
| Increase | 12% | 2 | 0% | 0 | 39% | 7 | ||||
| Decrease | 59% | 10 | 56% | 9 | 33% | 6 | ||||
| Stable | 29% | 5 | 44% | 7 | 28% | 5 | ||||
| Total | 17 | 16 | 18 | 0.042† | 0.460†† | 0.059†† | 0.923†† | |||
| Medial central condyle | ||||||||||
| Presence of BML at baseline: %, n | 11% | 12 | 10% | 10 | 8% | 9 | 0.801† | |||
| Baseline BML score | 1.08±0.29 | – | 1.00±0.00 | – | 1.22±0.44 | – | 0.269 | |||
| 36 months | ||||||||||
| Difference from baseline | −0.63±0.41 | 12 | −0.50±0.47 | 10 | 0.20±0.59 | 9 | 0.003 | 0.008 | 0.019 | >0.9999 |
| Increase | 0% | 0 | 0% | 0 | 40% | 2 | ||||
| Decrease | 63% | 5 | 50% | 4 | 20% | 1 | ||||
| Stable | 38% | 3 | 50% | 4 | 40% | 2 | ||||
| Total | 8 | 8 | 5 | 0.101† | ||||||
| Medial plateau | ||||||||||
| Presence of BML at baseline: %, n | 13% | 15 | 9% | 9 | 9% | 10 | 0.438† | |||
| Baseline BML score | 1.13±0.35 | – | 1.11±0.33 | – | 1.60±0.84 | – | 0.154 | |||
| 36 months | ||||||||||
| Difference from baseline | −0.50±0.60 | 15 | −0.25±0.43 | 9 | 0.0±0.47 | 10 | 0.069 | 0.089 | 0.560 | 0.974 |
| Increase | 0% | 0 | 0% | 0 | 17% | 1 | ||||
| Decrease | 42% | 5 | 25% | 2 | 17% | 1 | ||||
| Stable | 58% | 7 | 75% | 6 | 67% | 4 | ||||
| Total | 12 | 8 | 6 | 0.345† | ||||||
p Values were assessed using the *Kruskal–Wallis test and the **Mann–Whitney test with Bonferroni adjustment for multiple comparisons, or if categorical variables, the †χ2 test and the ††χ2 test with Bonferroni adjustment for multiple comparisons. p Values in bold are significantly different.
BML, bone marrow lesion; n, number of participants; SrRan, strontium ranelate.